03:22 AM EST, 11/04/2024 (MT Newswires) -- Verona Pharma ( VRNA ) reported a Q3 loss Monday of $0.07 per diluted share, wider than the loss of $0.02 a year earlier.

Analysts surveyed by Capital IQ expected a loss of $0.32 per share.

Revenue for the quarter ended Sept. 30 was $5.6 million. The company did not report any revenue a year earlier.

Analysts polled by Capital IQ expected $1.5 million.

As of Sept. 30, the company had $336 million in cash and cash equivalents, with an expected cash runway of until at least the end of 2026.

Price: 34.96, Change: -0.02, Percent Change: -0.06